It reduces appetite and slows gastric emptying through a single receptor pathway
Many progestin-only birth control methods, including the mini-pill, implants, and hormonal IUDs, are considered compatible with breastfeeding
The study included 37.1 million individuals with type 2 diabetes, including 810,390 new semaglutide users
Patients who need to start treatment immediately Those with type 2 diabetes (covered indication in most provinces) Patients who prefer a medication with longer real-world safety data Individuals whose insurance covers Ozempic but will not cover future medications Those who achieved satisfactory results on semaglutide previously Patients who can wait for optimal efficacy might consider holding for Retatrutide approval if their condition permits
Subjects were followed for three years or until the outcome occurred (or administrative censoring at the end of follow-up)
Early trial data show liver fat reductions exceeding those seen with semaglutide in comparable populations a meaningful clinical advantage for patients with overlapping metabolic conditions